Stanley Laman Group, Ltd. Akebia Therapeutics, Inc. Transaction History

Stanley Laman Group, Ltd.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Oct 20, 2020	SELL	$2.39 - $13.08 $757,469 - $4.15 Million	-316,933 Closed	0 $0
Q2 2020 Jul 20, 2020	SELL	$6.67 - $13.58 $14,273 - $29,061	-2,140 Reduced 0.67%	316,933 $4.3 Million
Q1 2020 May 12, 2020	BUY	$4.1 - $10.24 $26,502 - $66,191	6,464 Added 2.07%	319,073 $2.42 Million
Q1 2019 May 10, 2019	SELL	$5.41 - $8.73 $117,499 - $189,606	-21,719 Reduced 6.5%	312,609 $2.56 Million
Q4 2018 Feb 07, 2019	BUY	$5.39 - $9.15 $178,656 - $303,285	33,146 Added 11.01%	334,328 $1.85 Million
Q3 2018 Oct 30, 2018	SELL	$7.44 - $10.65 $299,884 - $429,269	-40,307 Reduced 11.8%	301,182 $2.66 Million
Q2 2018 Aug 09, 2018	BUY	$9.15 - $11.34 $247,855 - $307,177	27,088 Added 8.62%	341,489 $3.41 Million
Q1 2018 May 01, 2018	BUY	$9.53 - $15.68 $3 Million - $4.93 Million	314,401 New	314,401 $3 Million

120

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $324M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Stanley Laman Group, Ltd., based on Form 13F filings with the SEC.

Stay updated on Stanley Laman Group, Ltd. with notifications on news.